The impact of early normalization of haematocrit by erythropoietin on renal damage in the remnant kidney model.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Nephrology, Dialysis and Transplantation

• Publication date

  1998-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/NDT/13.9.2210PMID 9761499
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Renal function in predialysis children with chronic renal failure treated with erythropoietin

  1997cited by this paper
• Fetal proteins and chronic treatment with low-dose erythropoietin.

  1997cited by this paper
• Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention.

  1996cited by this paper
• The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease.

  1996cited by this paper
• The future of r-HuEPO.

  1995cited by this paper
• Starting r-HuEPO in chronic renal failure: when, why, and how?

  1995cited by this paper
• Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients.

  1995cited by this paper
• Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients.

  1994cited by this paper
• Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury.

  1994cited by this paper
• Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury.

  1994cited by this paper
• Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model.

  1992cited by this paper
• Effects of salt restriction on renal growth and glomerular injury in rats with remnant kidneys.

  1992cited by this paper
• Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. The US Recombinant Human Erythropoietin Predialysis Study Group.

  1991cited by this paper
• Bone marrow changes following treatment of renal anemia with erythropoietin.

  1991cited by this paper
• Recombinant human erythropoietin in predialysis patients.

  1991cited by this paper
• Anemia ameliorates progressive renal injury in experimental DOCA-salt hypertension.

  1991cited by this paper
• Recombinant human erythropoietin activates a broad spectrum of progenitor cells.

  1990cited by this paper
• Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin.

  1990cited by this paper
• Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells.

  1990cited by this paper
• Glomerular dynamics and salt balance in pregnant rats with renal hypertension.

  1989cited by this paper
• Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial.

  1989cited by this paper
• Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass.

  1988cited by this paper
• Mechanism of impaired urinary concentration in chronic primary glomerulonephritis.

  1985cited by this paper
• Anemia of end-stage renal disease (ESRD).

  1985cited by this paper
• Development of glomerular lesions in experimental long-term diabetes in the rat.

  1982cited by this paper
• Stereology: applications to biomedicalresearch.

  1971cited by this paper

• Renal risk‐benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model – hypertension, anaemia, inflammation and drug dose

  2016cites this paper
• Restoration of Haemoglobin Level Using Hydrodynamic Gene Therapy with Erythropoietin Does Not Alleviate the Disease Progression in an Anaemic Mouse Model for TGFβ1-Induced Chronic Kidney Disease

  2015cites this paper
• Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia

  2015cites this paper
• Erythropoietin attenuated vascular dysfunction and inflammation by inhibiting NADPH oxidase-derived superoxide production in nitric oxide synthase-inhibited hypertensive rat aorta.

  2012cites this paper
• Recombinant human erythropoietin ameliorated endothelial dysfunction and macrophage infiltration by increasing nitric oxide in hypertensive 5/6 nephrectomized rat aorta.

  2011cites this paper
• Rapid CKD progression in a new mouse kidney remnant model: strain-dependent resistance is overcome by angiotensin II

  2011cites this paper
• Erythropoietin prevents vascular inflammation and oxidative stress in subtotal nephrectomized rat aorta beyond haematopoiesis

  2010cites this paper
• Pharmacokinetics and Pharmacodynamics of an EPO-Mimetic Fusion Protein in a Model of Chronic Renal Insufficiency Anemia

  2010cites this paper
• Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model.

  2010cites this paper
• Epoetin Delta as an Antifibrotic Agent in the Remnant Kidney Rat: A Possible Role for Transforming Growth Factor Beta and Hepatocyte Growth Factor

  2010cites this paper
• Stability of target hemoglobin levels during the first year of epoetin treatment in patients with chronic kidney disease.

  2007cites this paper
• Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression.

  2007cites this paper
• Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.

  2006cites this paper
• Renin-Angiotensin-Aldosterone System Antihypertensive and Renal Protective Effects of Renin-Angiotensin System Blockade in Uremic Rats Treated With Erythropoietin

  2006cites this paper
• [Progression of renal insufficiency in the pre-end-stage renal disease setting].

  2003cites this paper
• Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.

  2001cites this paper
• [Factors in the progression of renal insufficiency during the 2 years preceding the use of dialysis].

  1999cites this paper